Epidemiologic and scientific research indicates that diet and other lifestyle factors have a significant influence on the risk of developing colon cancer. However, the influence of diet and lifestyle factors on the outcome of patients with established colon cancer is virtually unknown. Randomized clinical trials demonstrate a significant survival advantage for individuals with stage III colon cancer who receive adjuvant fluorouracil- based chemotherapy. Nonetheless, 40-45% of stage III patients receiving current adjuvant chemotherapy will develop metastases. Patients often seek to understand what, if any, diet and lifestyle will reduce their chances of cancer recurrence beyond standard surgery and post-operative adjuvant therapy. Moreover, how diet and lifestyle influence prognosis may depend, in part, on molecular characteristics of the tumor. During the previous funding period, we found that relative states of hyperinsulinemia and insulin resistance, including a history of type 2 diabetes, obesity, sedentary lifestyle, high intake of a Western pattern diet, high dietary glycemic load, and elevated plasma C-peptide conferred an increased risk of colon cancer recurrence. Additionally, recognizing the intersection of nutrient excess and derangements in cellular and molecular mediators of inflammation, we concurrently found that regular aspirin or selective COX-2 inhibitor use was associated with reduced cancer recurrence and mortality. In this competitive renewal application, (Aim 1) we propose to identify novel dietary and lifestyle risk factors for CRC recurrence and mortality, and, moreover, identify potential mechanisms of action through detailed, hypothesis-based molecular analysis of patient tumors. Additionally, recognizing that energy excess and insulin resistance may alternatively drive cancer recurrence through promotion of inflammation-related pathways, (Aim 2) we will further assess the role of anti- inflammatory medications to abrogate the increased risk of cancer recurrence associated with energy excess. Finally, (Aim 3) we will combine the available data to develop a novel comprehensive dietary risk prediction model for cancer recurrence and mortality, incorporating dietary/lifestyle factors with established clinical- pathologic covariates, and validate the model n 3 independent CRC patient cohorts to provide a more robust risk assessment tool for newly diagnosed CRC patients that can meaningfully inform clinical care and potentially incorporate lifestyle modification into CRC treatment recommendations. Many hypotheses would be interesting on their own, but the most unique strength of this proposal is our ability to assess simultaneously diet, medication, lifestyle factors, and molecular alterations in tumor tissue. Ultimately, we believe the proposed work will advance our understanding of CRC biology, identify interventions that can improve patient survival, and, with the extensive clinical, pathologic, and biomarker data available for analysis, inform clinicians how to maximally utilize these interventions to improve clinical care.

Public Health Relevance

While considerable evidence supports the role of diet and lifestyle on the risk of developing colorectal cancer, the effect that these factors play on the survival of patients with established colorectal cancer is largely unknown. Using the resources of a large clinical trial, we propose to define the influence of these factors on patient survival o provide valuable information on colorectal cancer biology and offer meaningful interventions to improve patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA118553-06
Application #
8817964
Study Section
Special Emphasis Panel (ZRG1-PSE-K (90))
Program Officer
Elena, Joanne W
Project Start
2007-05-07
Project End
2020-01-31
Budget Start
2015-03-02
Budget End
2016-01-31
Support Year
6
Fiscal Year
2015
Total Cost
$444,693
Indirect Cost
$177,397
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Kosumi, Keisuke; Hamada, Tsuyoshi; Koh, Hideo et al. (2018) The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. Am J Pathol 188:2839-2852
Liu, Li; Tabung, Fred K; Zhang, Xuehong et al. (2018) Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum. Clin Gastroenterol Hepatol 16:1622-1631.e3
AlDubayan, Saud H; Giannakis, Marios; Moore, Nathanael D et al. (2018) Inherited DNA-Repair Defects in Colorectal Cancer. Am J Hum Genet 102:401-414
Yang, Wanshui; Liu, Li; Masugi, Yohei et al. (2018) Calcium intake and risk of colorectal cancer according to expression status of calcium-sensing receptor (CASR). Gut 67:1475-1483
Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. JAMA Oncol 4:783-790
Hamada, Tsuyoshi; Liu, Li; Nowak, Jonathan A et al. (2018) Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. Eur J Cancer 103:98-107
Ma, Siyuan; Ogino, Shuji; Parsana, Princy et al. (2018) Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biol 19:142
Hamada, Tsuyoshi; Nowak, Jonathan A; Masugi, Yohei et al. (2018) Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells. J Natl Cancer Inst :
Guercio, Brendan J; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One 13:e0199244

Showing the most recent 10 out of 91 publications